Company news
Outlook Therapeutics, Inc. news in 2021
Outlook Therapeutics, Inc.'s news releases, calls and decks from 2021, newest first.
Outlook Therapeutics Reports Financial Results for Fiscal Year 2021 and Provides Corporate Update
December 21, 2021
Outlook Therapeutics Announces Closing of $57.5 Million Bought Deal, Including Full Exercise of Underwriter’s Option to Purchase Additional Shares
November 28, 2021
Outlook Therapeutics Increases Previously Announced Bought Deal Offering of Common Stock to $50 Million
November 22, 2021
Outlook Therapeutics Announces $10 Million Bought Deal Offering of Common Stock
November 22, 2021
Outlook Therapeutics Presents NORSE TWO Phase 3 Pivotal Safety and Efficacy Data for ONS-5010 / LYTENAVA™ (bevacizumab-vikg) at the Retina Subspecialty Day, American Academy of Ophthalmology (AAO) 2021 Annual Conference
November 12, 2021
Outlook Therapeutics Reports New Positive 12-Month Safety Data from Pivotal Phase 3 NORSE TWO Trial
September 27, 2021
Outlook Therapeutics Presents Positive NORSE THREE Safety Data for ONS-5010 / LYTENAVA™ (bevacizumab-vikg) at EURETINA Virtual 2021 Medical Conference
September 12, 2021
Outlook Therapeutics Reports Financial Results for Third Quarter of Fiscal Year 2021 and Provides Corporate Update
August 12, 2021
Outlook Therapeutics Reports Positive Efficacy and Safety Data from Pivotal Phase 3 NORSE TWO Trial of ONS-5010 / LYTENAVA™ (bevacizumab-vikg) for the Treatment of Wet AMD
August 2, 2021
Outlook Therapeutics Appoints C. Russell Trenary III as President and Chief Executive Officer
July 6, 2021
Outlook Therapeutics Announces Inclusion in the Russell 2000® Index
June 13, 2021
Outlook Therapeutics Reports Completion of Patient Dosing in the ONS-5010 Pivotal Phase 3 NORSE TWO Trial
June 7, 2021
Outlook Therapeutics Reports Financial Results for Second Quarter of Fiscal Year 2021 and Provides Corporate Update
May 13, 2021
Outlook Therapeutics to Host Virtual Clinical Day on May 20, 2021
May 11, 2021
Outlook Therapeutics Reports Positive Safety Profile from NORSE THREE Open-Label Safety Study for ONS-5010 / LYTENAVA™ (bevacizumab-vikg)
March 30, 2021
Outlook Therapeutics Reports Financial Results for First Quarter Fiscal Year 2021 and Provides Corporate Update
February 15, 2021
Outlook Therapeutics Reports Final Visit for Last Patient in Open-Label Safety Study for ONS-5010/LYTENAVA™ (bevacizumab-vikg)
February 10, 2021
Outlook Therapeutics’ Recent Financing Secures Funding to Support ONS-5010 / LYTENAVA™ (bevacizumab-vikg) Through Planned BLA Submission
February 3, 2021
Outlook Therapeutics Announces Closing of $35.0 Million Bought Deal
February 1, 2021
Outlook Therapeutics Increases Previously Announced Bought Deal Offering of Common Stock to $35.0 Million
January 27, 2021
Outlook Therapeutics Announces $10.0 Million Bought Deal Offering of Common Stock
January 27, 2021
Decks in 2021
- Corporate Update (August 2021)
Corporate update · 21 slides · Aug 3, 2021